v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 05, 2026
Jun. 29, 2025
Jul. 05, 2026
Jun. 29, 2025
Income Statement [Abstract]        
Total $ 9,024 $ 7,468 $ 16,624 $ 12,566
Cost of revenue 7,722 5,526 13,770 10,363
Gross profit 1,302 1,942 2,854 2,203
Operating expenses:        
Research and development 24,444 28,148 50,972 54,077
Selling, general and administrative 20,154 17,527 39,073 34,419
Total operating expenses 44,598 45,675 90,045 88,496
Loss from operations (43,296) (43,733) (87,191) (86,293)
Other income (expense):        
Change in fair value of common stock warrants 181 (5,885) 6,578 9,911
Gain on bargain purchase of assets 0 4,761 0 4,761
Interest income 5,134 2,427 10,910 4,861
Interest expense (6,521) (1,705) (13,529) (3,421)
Other income (expense), net 984 (992) 1,327 1,361
Total other income (expense), net (222) (1,394) 5,286 17,473
Loss before income tax benefit (43,518) (45,127) (81,905) (68,820)
Income tax benefit (441) (861) (570) (1,023)
Net loss (43,077) (44,266) (81,335) (67,797)
Net gain (loss) attributable to non-controlling interest (14) 262 (12) 241
Net loss attributable to Enovix $ (43,063) $ (44,528) $ (81,323) $ (68,038)
Net loss per share attributable to Enovix shareholders, basic (in dollars per share) [1] $ (0.20) $ (0.22) $ (0.37) $ (0.33)
Net loss per share attributable to Enovix shareholders, diluted (in dollars per share) [1] $ (0.20) $ (0.22) $ (0.37) $ (0.33)
Weighted average number of common shares outstanding, basic (in shares) [1] 218,502,098 204,819,119 217,908,465 204,086,108
Weighted average number of common shares outstanding, diluted (in shares) [1] 218,502,098 204,819,119 217,908,465 204,086,108
[1] As required by ASC 260, Earnings Per Share, the share and per share amounts presented in the above table for the fiscal quarter and fiscal year-to-date ended June 29, 2025 have been retroactively adjusted to reflect the warrant dividend issued in July 2025.